<DOC>
	<DOC>NCT01288404</DOC>
	<brief_summary>Hypothesis: Subconjunctival bevacizumab injection may potentially suppress neovascularization in pterygium, preventing or retarding the progression of recurrence.</brief_summary>
	<brief_title>Randomized Controlled Trial of Subconjunctival Bevacizumab Injection in Impending Recurrent Pterygium</brief_title>
	<detailed_description>1. Impending recurrent pterygium 2. Anti-VEGF therapy - Bevacizumab - Subconjunctival injection - Suppress neovascularization</detailed_description>
	<mesh_term>Pterygium</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Fluorometholone</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>1. Impending recurrent pterygium developed within 6 months following pterygium surgery either simple excision or excision with grafting. 2. Failure of conventional topical antiinflammatory therapy for impending recurrent pterygium which was defined by the progression of fibrovascular tissue over the excised area despite receiving treatment. 3. No history of any adjunctive treatment such as MMC, 5FU, periocular injection of corticosteroids and beta radiation. 4. No other ocular surface pathologies or coexisting ocular diseases. 5. No other ocular surgeries within the previous 6 months. 6. No history of allergy to the medications used in this study. 7. Good compliance with the study regimen and availability for the duration of the entire study period. 1. Platelet disorders 2. Hypertension 3. Pregnant or lactating women</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Bevacizumab, impending recurrent pterygium</keyword>
</DOC>